NO20006008L - Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer - Google Patents

Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer

Info

Publication number
NO20006008L
NO20006008L NO20006008A NO20006008A NO20006008L NO 20006008 L NO20006008 L NO 20006008L NO 20006008 A NO20006008 A NO 20006008A NO 20006008 A NO20006008 A NO 20006008A NO 20006008 L NO20006008 L NO 20006008L
Authority
NO
Norway
Prior art keywords
fatty acid
acid analogues
inflammatory
treatment
autoimmune diseases
Prior art date
Application number
NO20006008A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006008D0 (no
Inventor
Rolf Berge
Paal Aukrust
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Priority to NO20006008A priority Critical patent/NO20006008L/no
Publication of NO20006008D0 publication Critical patent/NO20006008D0/no
Priority to CA2457925A priority patent/CA2457925C/en
Priority to MXPA03004427A priority patent/MXPA03004427A/es
Priority to RU2003115423/15A priority patent/RU2259823C2/ru
Priority to BR0115527-0A priority patent/BR0115527A/pt
Priority to KR1020037007097A priority patent/KR100905335B1/ko
Priority to PCT/NO2001/000470 priority patent/WO2002043728A1/en
Priority to CNB018196969A priority patent/CN1296039C/zh
Priority to AU2002223162A priority patent/AU2002223162B2/en
Priority to AU2316202A priority patent/AU2316202A/xx
Priority to NZ525889A priority patent/NZ525889A/en
Priority to JP2002545699A priority patent/JP4368579B2/ja
Priority to DE60138834T priority patent/DE60138834D1/de
Priority to ES01998347T priority patent/ES2326159T3/es
Priority to HK05106536.3A priority patent/HK1073793B/xx
Priority to AT01998347T priority patent/ATE432071T1/de
Priority to US10/416,378 priority patent/US8088825B2/en
Priority to EP01998347A priority patent/EP1351672B1/de
Publication of NO20006008L publication Critical patent/NO20006008L/no
Priority to NO20032054A priority patent/NO324557B1/no
Priority to ZA200303668A priority patent/ZA200303668B/en
Priority to US13/340,157 priority patent/US20120101161A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
NO20006008A 2000-11-28 2000-11-28 Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer NO20006008L (no)

Priority Applications (21)

Application Number Priority Date Filing Date Title
NO20006008A NO20006008L (no) 2000-11-28 2000-11-28 Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
EP01998347A EP1351672B1 (de) 2000-11-28 2001-11-27 Fettsäureanaloge zur behandlung von entzündungs- und autoimmunerkrankungen
NZ525889A NZ525889A (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
DE60138834T DE60138834D1 (de) 2000-11-28 2001-11-27 Fettsäureanaloge zur behandlung von entzündungs- und autoimmunerkrankungen
RU2003115423/15A RU2259823C2 (ru) 2000-11-28 2001-11-27 Аналоги жирных кислот для лечения воспалительных и аутоиммунных расстройств
BR0115527-0A BR0115527A (pt) 2000-11-28 2001-11-27 Análogos de ácido graxo para o tratamento de distúrbios imflamatórios e autoimunes
KR1020037007097A KR100905335B1 (ko) 2000-11-28 2001-11-27 염증성 및 자가 면역성 장애를 치료하기 위한 지방산 동족체
PCT/NO2001/000470 WO2002043728A1 (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
CNB018196969A CN1296039C (zh) 2000-11-28 2001-11-27 治疗炎症和自身免疫性疾病的脂肪酸类似物
AU2002223162A AU2002223162B2 (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
AU2316202A AU2316202A (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
CA2457925A CA2457925C (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
JP2002545699A JP4368579B2 (ja) 2000-11-28 2001-11-27 炎症障害および自己免疫障害の治療用の脂肪酸アナログ
MXPA03004427A MXPA03004427A (es) 2000-11-28 2001-11-27 Analogos de acido graso para el tratamiento de desordenes inflamatorios y autoinmunes.
ES01998347T ES2326159T3 (es) 2000-11-28 2001-11-27 Analogos de acidos grasos para el tratamiento de enfermedades inflamatorias y autoinmunes.
HK05106536.3A HK1073793B (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
AT01998347T ATE432071T1 (de) 2000-11-28 2001-11-27 Fettsäureanaloge zur behandlung von entzündungs- und autoimmunerkrankungen
US10/416,378 US8088825B2 (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
NO20032054A NO324557B1 (no) 2000-11-28 2003-05-08 Anvendelse av fettsyreanaloger for a hindre og/eller behandle inflammatoriske og/eller autoimmune forstyrrelser.
ZA200303668A ZA200303668B (en) 2000-11-28 2003-05-13 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders.
US13/340,157 US20120101161A1 (en) 2000-11-28 2011-12-29 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20006008A NO20006008L (no) 2000-11-28 2000-11-28 Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer

Publications (2)

Publication Number Publication Date
NO20006008D0 NO20006008D0 (no) 2000-11-28
NO20006008L true NO20006008L (no) 2002-05-29

Family

ID=19911849

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006008A NO20006008L (no) 2000-11-28 2000-11-28 Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer

Country Status (17)

Country Link
US (2) US8088825B2 (de)
EP (1) EP1351672B1 (de)
JP (1) JP4368579B2 (de)
KR (1) KR100905335B1 (de)
CN (1) CN1296039C (de)
AT (1) ATE432071T1 (de)
AU (2) AU2002223162B2 (de)
BR (1) BR0115527A (de)
CA (1) CA2457925C (de)
DE (1) DE60138834D1 (de)
ES (1) ES2326159T3 (de)
MX (1) MXPA03004427A (de)
NO (1) NO20006008L (de)
NZ (1) NZ525889A (de)
RU (1) RU2259823C2 (de)
WO (1) WO2002043728A1 (de)
ZA (1) ZA200303668B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
CN100351259C (zh) 2002-06-20 2007-11-28 Icvec有限公司 含硫的磷脂衍生物
WO2005073164A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
AU2005264782B2 (en) * 2004-07-19 2010-12-16 Thia Medica As Composition comprising protein material and non-oxidizable fatty acid entities
WO2009006668A1 (en) * 2007-02-05 2009-01-15 Children, Youth And Women's Health Service Modulators of antigen-dependent t cell proliferation
DE102011050519A1 (de) * 2011-05-20 2012-11-22 Universität Rostock Alkylschwefelalkansäurederivate und ihre pharmazeutisch verträglichen Salze zur Behandlung chronisch entzündlicher Erkrankungen
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
AU2014228387B2 (en) 2013-03-11 2016-09-01 Sciadonics, Inc. Lipid compositions containing bioactive fatty acids
AU2018354090B2 (en) 2017-10-23 2024-10-24 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
WO2019226572A1 (en) 2018-05-23 2019-11-28 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
EP3908374A4 (de) 2019-01-09 2022-12-28 Epitracker, Inc. Zusammensetzungen und verfahren zur diagnose und behandlung von neurodegenerativen erkrankungen
EP3934639A4 (de) 2019-03-04 2023-01-11 Epitracker, Inc. Fettsäureanaloge und deren verwendung zur behandlung von kognitiven beeinträchtigungen, verhaltenszuständen und chronischen schmerzen
WO2023080939A1 (en) 2021-11-03 2023-05-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56164120A (en) * 1980-05-22 1981-12-17 Chisso Corp Antitumor agent
FR2631339B1 (fr) * 1988-05-10 1990-11-16 Cird Nouveaux eicosanoides sulfures et leur application en pharmacie et en cosmetique
DE4120917A1 (de) * 1991-06-25 1993-01-07 Basf Ag Ester von fettsaeuren mit aminoalkoholen zur verwendung bei der bekaempfung von krankheiten
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
IL103932A (en) * 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5618955A (en) 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
DE69524639T2 (de) * 1994-10-13 2002-08-08 Peptech Ltd., North Ryde Modifizierte mehrfach ungesättigte fettsäuren
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
EP0904072A4 (de) 1996-04-12 2003-07-30 Peptide Technology Pty Ltd Verfahren zur behandlung von immuno-pathologien unter verwendung mehrfach ungesättigter fetzäuren
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds

Also Published As

Publication number Publication date
US20120101161A1 (en) 2012-04-26
BR0115527A (pt) 2003-09-23
AU2002223162B2 (en) 2006-11-30
RU2259823C2 (ru) 2005-09-10
ES2326159T3 (es) 2009-10-02
NZ525889A (en) 2004-10-29
KR20030055322A (ko) 2003-07-02
MXPA03004427A (es) 2004-05-04
ZA200303668B (en) 2004-01-30
CN1633284A (zh) 2005-06-29
US20050165103A1 (en) 2005-07-28
HK1073793A1 (en) 2005-10-21
CN1296039C (zh) 2007-01-24
CA2457925A1 (en) 2002-06-06
AU2316202A (en) 2002-06-11
JP2004514693A (ja) 2004-05-20
DE60138834D1 (de) 2009-07-09
EP1351672B1 (de) 2009-05-27
KR100905335B1 (ko) 2009-07-01
CA2457925C (en) 2013-03-26
WO2002043728A1 (en) 2002-06-06
ATE432071T1 (de) 2009-06-15
US8088825B2 (en) 2012-01-03
EP1351672A1 (de) 2003-10-15
NO20006008D0 (no) 2000-11-28
JP4368579B2 (ja) 2009-11-18

Similar Documents

Publication Publication Date Title
NO20006008D0 (no) Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
EA199800119A1 (ru) Ингибиторы адгезии клеток
EE05423B1 (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
DE69625332D1 (de) Zelle adhäsion hemmenden verbindungen
AP2001002217A0 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
CY1110259T1 (el) Ανοσορυθμιστης
SG124234A1 (en) Cell adhesion inhibitors
ATE356113T1 (de) Probucolbernsteinsäureester zur hemmung der expression von vcam-1
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
BR0008059A (pt) Composições de valdecoxib
SE9802794D0 (sv) New compounds
SE9603725D0 (sv) New teatment
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE60131393D1 (de) Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände
DK1342410T3 (da) Anvendelse af en galaninagonist til fremstilling af et medikament til forbedring af hukommelse og andre kognitive funktioner
EA200300639A1 (ru) Применение sarp-1 для лечения и/или предупреждения склеродермии
WO2001081328A3 (en) Thiazolidinedione analogues and their use for the treatment of diabetes
AR040600A1 (es) Composicion farmaceutica estable que comprende eritropoietina
BR0311248A (pt) Kit de contracepção e/ou de hrt, usos de um éster de etonogestrel de ação prolongada, de um éster de etonogestrel de ação prolongada em conjunto com um éster de andrógeno de ação prolongada e de um éster de etonogestrel de ação prolongada em conjunto com um estrogênio, e, métodos de contracepção e /ou de hrt e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino
ATE514426T1 (de) Formulierungen zur verringerung oder eliminierung der toxizität von umwelthormonen mit ursodesoxycholsäure
NO20032054L (no) Fettsyreanaloger for behandling av inflammatoriske lidelser og autoimmune forstyrrelser
NO982854D0 (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes
RU2007138266A (ru) Комбинация ингибитора стероидсульфатазы и аскомицина
ATE269095T1 (de) Verfahren zur herstellung antitumoraler th1- zellen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application